GLYCOT THERAPEUTICS LLC

Ellicott City, MD · Biotech · Private

Proprietary chemoenzymatic glycan-remodeling platform for site-specific antibody conjugation enabling antibody-drug conjugates (ADCs) and other functional molecule-antibody conjugates

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · glycot.com

Sector: Biotech
Headquarters: Ellicott City, MD
Total capital: $8M

Federal grants: $8M; 17 awards · 2017–2025; Rank in peer group#33 of 36
Private capital raised: None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
Federal contracts: None on recordNo federal contract awards found.
Granted patents: None on recordNo USPTO grants. Applications publish after 18 months.

Capital timeline

Latest events

Feb 2025Federal grantHealth and Human S · Phase II · Development of streamlined one-pot chemoenzymatic glycan remodeling systems for antibody conjugation$978K
Feb 2024Federal grantHealth and Human S · Phase II · Development of streamlined one-pot chemoenzymatic glycan remodeling systems for antibody conjugation$758K
Jun 2023Federal grantHealth and Human S · Phase I · Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation$90K
Jul 2022Federal grantHealth and Human S · Phase II · Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$714K
May 2022Federal grantHealth and Human S · Phase I · Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation$321K
Apr 2022Federal grantHealth and Human S · Phase I · Development of a facile, robust, scalable, and versatile chemoenzymatic glycan-remodeling approach for site-specific antibody conjugation$232K
Jul 2021Federal grantHealth and Human S · Phase II · Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$775K

Show 10 earlier federal awards

Jul 2020Federal grantHealth and Human S · Phase I · Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$150K
Mar 2020Federal grantHealth and Human S · Phase II · Chemoenzymatic Glycan Remodeling of IVIG for Improved Anti-inflammatory Activity$545K
Aug 2019Federal grantHealth and Human S · Phase I · Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$300K
Jul 2019Federal grantHealth and Human S · Phase I · Development of streamlined chemoenzymatic glycan remodeling systems for antibodies and other important glycoproteins$150K
Apr 2019Federal grantHealth and Human S · Phase II · Chemoenzymatic Glycan Remodeling of IVIG for Improved Anti-inflammatory Activity$1.3M
Apr 2019Federal grantHealth and Human S · Phase II · Chemoenzymatic Glycan Remodeling of IVIG for Improved Anti-inflammatory Activity$714K
Apr 2018Federal grantHealth and Human S · Phase I · Chemoenzymatic synthesis of stable isotope-labeled glycopeptides as internal standards for glycosylation quantitation$293K
Mar 2018Federal grantHealth and Human S · Phase I · Chemoenzymatic synthesis of stable isotope-labeled glycopeptides as internal standards for glycosylation quantitation$293K
Aug 2017Federal grantHealth and Human S · Phase I · Chemoenzymatic glycan remodeling of IVIG for improved anti inflammatory activity$219K
Jul 2017Federal grantHealth and Human S · Phase I · Chemoenzymatic glycan remodeling of IVIG for improved anti-inflammatory activity$219K

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 36 peers

Line = median

Biotech · Platform

Federal grantsBelow median

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

No founders are linked to this company yet.

Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.

Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026

Claim this profile to add your team

What it has protected

No granted patents are on record.

USPTO usually publishes applications 18 months after filing, so recent applications may not be visible yet. Patents assigned under a different entity name won’t match.

Checked: USPTO granted patents and published applications · Oct 23, 2026

SVISION, LLC.Similar federal contract value in Biotech · null in contracts
RIBO-THERAPEUTICS LLCSimilar federal contract value in Biotech · null in contracts
FGF Therapeutics INC.Similar federal contract value in Biotech · null in contracts
PROBIOME THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
ACCUNOVO BIOTECHNOLOGIES INCSimilar federal contract value in Biotech · null in contracts
YOURCHOICE THERAPEUTICS INCSimilar federal contract value in Biotech · null in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.